...
首页> 外文期刊>American journal of clinical pathology. >A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.
【24h】

A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.

机译:一种新颖的流式细胞仪抗体组,用于区分Burkitt淋巴瘤与CD10 +弥漫性大B细胞淋巴瘤。

获取原文
获取原文并翻译 | 示例

摘要

Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs. Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma. Our goal was to determine whether use of these markers would aid in the differential diagnosis of BL vs CD10+ DLBCL by flow cytometric immunophenotyping (FCI). Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL). Multiparameter FCI was performed using the following antibodies: CD18, CD20, CD43, CD44, and CD54 and isotype controls. Expression of CD44 and CD54 was detected at a significantly lower level in BL compared with CD10+ DLBCL (P = .001 and P = .01, respectively). There was not a significant difference in expression of CD18 and CD43. Our data show that expression of CD44 and CD54 differs significantly between BL and CD10+ DLBCL.
机译:由于伯基特氏淋巴瘤(BL)和CD10 +弥漫性大B细胞淋巴瘤(DLBCL)的治疗方法不同,因此必须进行快速,准确的鉴别诊断。最近的研究已经表征了在这两种类型的淋巴瘤中差异表达的几种抗原。我们的目标是通过流式细胞术免疫分型(FCI)确定使用这些标记物是否有助于BL与CD10 + DLBCL的鉴别诊断。鉴定了23例CD10 + B细胞淋巴瘤和可用冷冻保存的样本(13 BL和10 CD10 + DLBCL)。使用以下抗体进行多参数FCI:CD18,CD20,CD43,CD44和CD54和同种型对照。与CD10 + DLBCL相比,BL中CD44和CD54的表达水平显着降低(分别为P = .001和P = .01)。 CD18和CD43的表达没有显着差异。我们的数据表明,BL和CD10 + DLBCL之间CD44和CD54的表达差异显着。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号